CompletedNot Applicable

Efficacy of Erector Spinae Plane (ESP) Block in Patients With Inflammatory Bowel Disease (IBD)

Canada67 participantsStarted 2021-07-21

Plain-language summary

This will be a prospective, double-blind randomized controlled clinical trial. There will be two arms of treatment: intervention and control group. Preoperatively patients will be allocated at random to receive ultrasound guided bilateral ESP block either with the local anesthetic (intervention group) normal saline (control group). The aim of this study is to examine the effect of ESP block to increase the Quality of Recovery (measured via QoR-15 total score) and decrease opioid consumption.

Who can participate

Age range18 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Adults (18-85 years old) diagnosed with IBD
✓. ASA physical status I-III
✓. IBD abdominal laparoscopic assisted surgeries under general anesthesia

Exclusion criteria

✕. Unable to communicate in English
✕. Unstable requiring emergency surgery
✕. Open laparotomies
✕. Morbidly obese
✕. Pregnant
✕. On chronic opioid treatment
✕. Known allergies to local anesthetics
✕. Altered mental status

What they're measuring

Quality of Recovery (via QoR-15) total score

Timeframe: baseline, 24 hours, 48 hours and 72 hours postoperatively

Trial details

NCT IDNCT06230003

SponsorSamuel Lunenfeld Research Institute, Mount Sinai Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-12-17

View on ClinicalTrials.gov More Opioid Use trials